Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

Evaluation of 188Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model

Authors Huang FYJ, Lee TW, Chang CH, Chen LC, Hsu WH, Chang CW, Lo JM

Received 17 October 2014

Accepted for publication 26 November 2014

Published 9 January 2015 Volume 2015:10(1) Pages 463—473

DOI https://doi.org/10.2147/IJN.S75955

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Thomas J Webster

Feng-Yun J Huang,1 Te-Wei Lee,2 Chih-Hsien Chang,2 Liang-Cheng Chen,2 Wei-Hsin Hsu,2 Chien-Wen Chang,1 Jem-Mau Lo1

1Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan; 2Institute of Nuclear Energy Research, Longtan, Taiwan

Purpose:
In this study, the 188Re-labeled PEGylated nanoliposome (188Re-liposome) was prepared and evaluated as a therapeutic agent for glioma.
Materials and methods: The reporter cell line, F98luc was prepared via Lentivector expression kit system and used to set up the orthotopic glioma-bearing rat model for non-invasive bioluminescent imaging. The maximum tolerated dose applicable in Fischer344 rats was explored via body weight monitoring of the rats after single intravenous injection of 188Re-liposome with varying dosages before the treatment study. The OLINDA/EXM 1.1 software was utilized for estimating the radiation dosimetry. To assess the therapeutic efficacy, tumor-bearing rats were intravenously administered 188Re-liposome or normal saline followed by monitoring of the tumor growth and animal survival time. In addition, the histopathological examinations of tumors were conducted on the 188Re-liposome-treated rats.
Results: By using bioluminescent imaging, the well-established reporter cell line (F98luc) showed a high relationship between cell number and its bioluminescent intensity (R2=0.99) in vitro; furthermore, it could also provide clear tumor imaging for monitoring tumor growth in vivo. The maximum tolerated dose of 188Re-liposome in Fischer344 rats was estimated to be 333 MBq. According to the dosimetry results, higher equivalent doses were observed in spleen and kidneys while very less were in normal brain, red marrow, and thyroid. For therapeutic efficacy study, the progression of tumor growth in terms of tumor volume and/or tumor weight was significantly slower for the 188Re-liposome-treated group than the control group (P<0.05). As a result, the lifespan of glioma-bearing rats treated with 188Re-liposome was prolonged 10.67% compared to the control group.
Conclusion: The radiotherapeutic evaluation by dosimetry and survival studies have demonstrated that passive targeting 188Re-liposome via systemic administration can significantly prolong the lifespan of orthotopic glioma-bearing rats while maintaining reasonable systemic radiation safety. Therefore, 188Re-liposome could be a potential therapeutic agent for glioblastoma multiforme treatment.

Keywords: 188Re, liposome, radionuclide therapy, bioluminescent imaging, glioma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Real-time analysis of dual-display phage immobilization and autoantibody screening using quartz crystal microbalance with dissipation monitoring

Rajaram K, Losada-Pérez P, Vermeeren V, Hosseinkhani B, Wagner P, Somers V, Michiels L

International Journal of Nanomedicine 2015, 10:5237-5247

Published Date: 19 August 2015

Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis

Zhou L, Duan X, Zeng S, Men K, Zhang X, Yang L, Li X

International Journal of Nanomedicine 2015, 10:5205-5218

Published Date: 18 August 2015

Effect of surface roughness on osteogenesis in vitro and osseointegration in vivo of carbon fiber-reinforced polyetheretherketone–nanohydroxyapatite composite

Deng Y, Liu X, Xu A, Wang L, Luo Z, Zheng Y, Deng F, Wei J, Tang Z, Wei S

International Journal of Nanomedicine 2015, 10:1425-1447

Published Date: 17 February 2015

Detection of acute deterioration in health status visit among COPD patients by monitoring COPD assessment test score

Pothirat C, Chaiwong W, Limsukon A, Deesomchok A, Liwsrisakun C, Bumroongkit C, Theerakittikul T, Phetsuk N

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:277-282

Published Date: 3 February 2015

Association of genetic polymorphisms with chronic obstructive pulmonary disease in the Hainan population: a case-control study

Ding YP, Yang DL, Xun XJ, Wang ZF, Sun P, Xu DC, He P, Niu H, Jin TB

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:7-13

Published Date: 17 December 2014

Validation of the custo screen 400 ambulatory blood pressure-monitoring device according to the European Society of Hypertension International Protocol revision 2010

Bramlage P, Deutsch C, Krüger R, Wolf A, Müller P, Zwingers T, Beime B, Mengden T

Vascular Health and Risk Management 2014, 10:303-309

Published Date: 13 May 2014

Monitoring human papillomavirus prevalence in urine samples: a review [Corrigendum]

Enerly E, Olofsson C, Nygård M

Clinical Epidemiology 2013, 5:371-372

Published Date: 18 September 2013

Transitions of care in anticoagulated patients

Michota F

Journal of Multidisciplinary Healthcare 2013, 6:215-228

Published Date: 20 June 2013